AU2002359706A1 - Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia - Google Patents

Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia

Info

Publication number
AU2002359706A1
AU2002359706A1 AU2002359706A AU2002359706A AU2002359706A1 AU 2002359706 A1 AU2002359706 A1 AU 2002359706A1 AU 2002359706 A AU2002359706 A AU 2002359706A AU 2002359706 A AU2002359706 A AU 2002359706A AU 2002359706 A1 AU2002359706 A1 AU 2002359706A1
Authority
AU
Australia
Prior art keywords
neuropeptide
dementia
anxiety
receptor antagonists
treating depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002359706A
Inventor
Douglas J. Macneil
Lauren P. Shearman
Leonardus H. T. Van Der Ploeg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2002359706A1 publication Critical patent/AU2002359706A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002359706A 2001-12-17 2002-12-13 Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia Abandoned AU2002359706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34154201P 2001-12-17 2001-12-17
US60/341,542 2001-12-17
PCT/US2002/040012 WO2003051397A1 (en) 2001-12-17 2002-12-13 Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia

Publications (1)

Publication Number Publication Date
AU2002359706A1 true AU2002359706A1 (en) 2003-06-30

Family

ID=23338019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002359706A Abandoned AU2002359706A1 (en) 2001-12-17 2002-12-13 Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia

Country Status (2)

Country Link
AU (1) AU2002359706A1 (en)
WO (1) WO2003051397A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540197A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
US20110166135A1 (en) * 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020820A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
AU7079498A (en) * 1997-04-23 1998-11-13 Banyu Pharmaceutical Co., Ltd. Neuropeptide y receptor antagonist
ATE345330T1 (en) * 1997-08-25 2006-12-15 Bayer Corp HETEROCYCLIC KETONES AS NPY Y5 ANTAGONISTS
DE69929235T2 (en) * 1998-11-10 2006-08-24 Merck & Co., Inc. SPIRO INDOLE AS Y5 RECEPTOR ANTAGONISTS
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same

Also Published As

Publication number Publication date
WO2003051397A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
AU2001294547A1 (en) Substituted urea neuropeptide y y5 receptor antagonists
IL159643A0 (en) Substituted urea neuropeptide y y5 receptor antagonists
HK1083505A1 (en) Ccr5 antagonists useful for treating aids
AU2002234056A1 (en) Heteroaryl urea neuropeptide Y Y5 receptor antagonists
SG116458A1 (en) Crane and method for controlling the crane.
WO2003004529A3 (en) Ephrin-tie receptor materials and methods
AU2001293936A1 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
IL162270A0 (en) Compounds and uses thereof for decreasing activityof hormone-sensitive lipase
AU2002341834A1 (en) Antagonists
EP1436394A4 (en) Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
HK1075037A1 (en) Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
AU2003251739A1 (en) New neuropeptide y y5 receptor antagonists
AU2001251083A1 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
AU2003239280A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
GB2392483B (en) Work-assembling auxiliary device, and work-assembling process
EP1359915A4 (en) Urotensin-ii receptor antagonists
AU2001246494A1 (en) Condensed thiazolamines and their use as neuropeptide y5 antagonists
PL365751A1 (en) Thermal-break device for concrete floor, and floor equipped therewith
EP1431464A4 (en) Counterweight and method for recycling the same
EP1351687A4 (en) Urotensin-ii receptor antagonists
AU2002359706A1 (en) Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
AU2003206014A8 (en) Neuropeptide receptor and uses thereof
AU2002240902A1 (en) Mat, and device for producing said mat
AU2003267241A1 (en) Method for treating depression and/or anxiety

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase